Kakuta Shinsuke, Takayama Wataru, Kou Tetsumori, Satou Mamoru, Sugaya Makoto
Dept. of Surgery, Chiba Prefectural Sawara Hospital.
Gan To Kagaku Ryoho. 2016 Jan;43(1):129-32.
We report a case of descending colon adenocarcinoma with neuroendocrine differentiation that was effectively treated with FOLFIRI plus bevacizumab. A 70-year-old man underwent a colonoscopy and was found to have a type 2 tumor of the descending colon. A well-to-moderately differentiated adenocarcinoma was diagnosed by biopsy. A preoperative CT scan showed paraaortic lymph node and liver metastasis, and that the tumor was directly invading the spleen. The patient underwent a left hemicolectomy with resection of the pancreas tail, spleen, and diaphragm. The pathological diagnosis was adenocarcinoma with less than 30% neuroendocrine differentiation in the primary tumor and almost 100% neuroendocrine differentiation in the metastatic lymph nodes. After surgery, FOLFIRI plus bevacizumab treatment was initiated. After 33 treatment cycles, the paraaortic lymph node and liver metastasis disappeared and the patient has remained progression-free to date. Adenocarcinoma with neuroendocrine differentiation of the colon is rare and an effective chemotherapy has not yet been established. We report this case with a review of the literature.
我们报告一例降结肠癌伴神经内分泌分化,经FOLFIRI联合贝伐单抗治疗有效。一名70岁男性接受结肠镜检查,发现降结肠有2型肿瘤。活检诊断为中分化腺癌。术前CT扫描显示主动脉旁淋巴结和肝转移,且肿瘤直接侵犯脾脏。患者接受了左半结肠切除术,切除胰尾、脾脏和膈肌。病理诊断为原发性肿瘤神经内分泌分化小于30%,转移性淋巴结几乎100%神经内分泌分化。术后开始FOLFIRI联合贝伐单抗治疗。经过33个治疗周期后,主动脉旁淋巴结和肝转移消失,患者至今无疾病进展。结肠神经内分泌分化腺癌罕见,尚未确立有效的化疗方案。我们报告此病例并复习文献。